MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
4.800
-0.140
-2.83%
After Hours: 4.800 0 0.00% 18:21 04/12 EDT
OPEN
4.900
PREV CLOSE
4.940
HIGH
5.00
LOW
4.730
VOLUME
211.67K
TURNOVER
0
52 WEEK HIGH
7.28
52 WEEK LOW
3.890
MARKET CAP
208.45M
P/E (TTM)
-3.6954
1D
5D
1M
3M
1Y
5Y
Zevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug Portfolio
TipRanks · 2d ago
Zevra Therapeutics Bolsters Finance Strategy with $100M Loan
TipRanks · 3d ago
Zevra Therapeutics retires existing debt with new $100M credit facility
Zevra Therapeutics retires existing debt with new $100M credit facility. The stock price moved 2.8% higher on Wednesday during pre-market trading. The company entered into a new credit facility of up to $100m in committed capital in three tranches.
Seeking Alpha · 3d ago
ZEVRA THERAPEUTICS INC: HAS RETIRED ITS COMBINED EXISTING DEBT OF APPROXIMATELY $43.1M
Reuters · 3d ago
Press Release: Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility. New credit facility provides $100 million in committed capital in three tranches. The Company has retired its combined existing debt of approximately $43.1 million.
Dow Jones · 3d ago
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Zevra Therapeutics, Inc. Has entered into a new credit facility provided by leading biotech investors. New credit facility provides up to $100M in committed capital in three tranches. The Company has retired its combined existing debt of approximately $43.1M.
Barchart · 3d ago
Weekly Report: what happened at ZVRA last week (0401-0405)?
Weekly Report · 5d ago
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has seen its revenue and earnings per share forecasts revised downwards. Six analysts are now forecasting revenues of US$29m in 2024. This is a 6.8% increase in sales compared to the last year. The consensus price target for the company is now US$19.00.
Simply Wall St · 6d ago
More
About ZVRA
Zevra Therapeutics, Inc. is a rare disease company melding science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA. Its pipeline also includes EDSIVO and others.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.